Stantec Q3 2026: Record EBITDA margin and raised outlook, but organic growth stays mid-single digits

What happened

Stantec reported Q3 2026 net revenue of $1.9 billion, up 9.4% year-over-year, with organic growth of 5.3% and acquisition growth of 2.6%. Adjusted EBITDA margin reached a record 20.2%, up 120 basis points from the prior-year period, driving adjusted EBITDA up 16.6% to $53.7 million higher. Adjusted EPS of $1.89 compared with diluted EPS of $1.60, and the company raised its profitability outlook. The margin beat validates the operating leverage story, but organic growth remains mid-single digits, in line with recent quarters but below earlier double-digit total growth. These results reinforce earnings quality but offer little new catalyst to re-rate an already expensive stock.

Implication

The record EBITDA margin and raised guidance affirm Stantec's ability to expand profitability even as growth moderates, suggesting the business is more resilient than previously modeled; however, with the stock at ~$98 and limited valuation cushion, investors should wait for a better entry or evidence that organic growth can reaccelerate before adding.

Thesis delta

Our prior WAIT thesis emphasized high-teens EPS growth and margin sustainability, but noted limited upside at current valuation. The new results show even stronger margin expansion (20.2% vs ~18% expected) and raised guidance, suggesting the operating model is more efficient than we anticipated. However, organic growth remains at 5.3%, indicating that the growth engine is not accelerating, and the stock still trades at a premium, so we maintain our WAIT stance with a slightly higher conviction on margin durability.